VivoSeq
Other

EGFR

1

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

EGFR is an early-stage landscape with 1 program across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

TNO155

Novartis

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

10

clinical trials

Completed6 · 60%
Unknown status3 · 30%
Terminated1 · 10%

Clinical Trials

Trial Activity

10 trials

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)
Completed·—·Phase 3·NCT02521181·194 enrolled
Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects
Completed·—·Phase 2·NCT01892527·43 enrolled
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
Completed·SSymphogen A/S·Phase 2·NCT01417936·26 enrolled
Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash
Completed·MMayo Clinic·Phase 1·NCT03471364·58 enrolled
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
Completed·NNational Taiwan University Hospital·N/A·NCT04047680·441 enrolled
E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C
Completed·IInstituto Oncológico Dr Rosell·Phase 1/2·NCT03623750·23 enrolled
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors
Terminated·Novartis logoNovartis·Phase 1·NCT03114319·227 enrolled
Dual Inhibition of EGFR Signalling Using the Combination of Cetuximab and Erlotinib
Unknown status·AAustin Health·Phase 2·NCT00784667·50 enrolled
Uncommon EGFR AZD9291
Unknown status·SSamsung Medical Center·Phase 2·NCT03424759·37 enrolled
A Study to Investigate Nicotinic Acid on VEGFR Inhibitor-Associated Hand-Foot Skin Reactions
Unknown status·FFirst People's Hospital of Hangzhou·Phase 2·NCT04242927·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)